Extendicare (EXE) Stock Price, News & Analysis

Company Overview

Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties. It operates through the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. The company was incorporated in 1968 and is based in Markham, Canada.

Key Stats

• Today's Range: C$9.27 to C$9.36
• 50-Day Range: C$7.54 to C$9.48
• 52-Week Range: C$5.75 to C$9.52
• Volume: 45,245 shs
• Average Volume: 133,478 shs
• Market Capitalization: C$776.27 million
• P/E Ratio: 13.68
• Dividend Yield: 5.16%
• Price Target: C$9.17
• Consensus Rating: Moderate Buy

Extendicare Stock Analysis - MarketRank™

Extendicare scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Extendicare has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Extendicare has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Extendicare is 13.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.47.

Price to Earnings Ratio vs. Sector

The P/E ratio of Extendicare is 13.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.27.

Price to Book Value per Share Ratio

Extendicare has a P/B Ratio of 7.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for EXE.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Extendicare is a leading dividend payer. It pays a dividend yield of 5.14%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Extendicare does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Extendicare is 70.59%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for EXE.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.53

News Sentiment

Extendicare has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Extendicare this week, compared to 1 article on an average week.

Search Interest

9 people have searched for EXE on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Extendicare to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Extendicare insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.92% of the stock of Extendicare is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 19.16% of the stock of Extendicare is held by institutions.

EXE Stock Analysis - Frequently Asked Questions

How have EXE shares performed this year?

Extendicare's stock was trading at C$7.28 on January 1st, 2024. Since then, EXE stock has increased by 27.7% and is now trading at C$9.30.
View the best growth stocks for 2024 here.

How were Extendicare's earnings last quarter?

Extendicare Inc. (TSE:EXE) issued its quarterly earnings results on Monday, August, 12th. The company reported $0.29 earnings per share for the quarter. The firm earned $348.48 million during the quarter, compared to analyst estimates of $360.20 million. Extendicare had a trailing twelve-month return on equity of 60.00% and a net margin of 4.28%.

How do I buy shares of Extendicare?

Shares of EXE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Extendicare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Extendicare investors own include Enbridge (ENB), Enterprise Products Partners (EPD), Algonquin Power & Utilities (AQN), Bank of Nova Scotia (BNS), NVIDIA (NVDA), Pembina Pipeline (PPL) and BCE (BCE).

Company Calendar

• Last Earnings: 8/12/2024
• Ex-Dividend for 10/15 Dividend: 9/27/2024
• Dividend Payable: 10/15/2024
• Today: 10/17/2024
• Ex-Dividend for 11/15 Dividend: 10/31/2024
• Next Earnings (Confirmed): 11/12/2024
• Dividend Payable: 11/15/2024

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Medical Care Facilities
• Sub-Industry: N/A
• Current Symbol: TSE:EXE
• CUSIP: N/A
• CIK: N/A
• Web: www.extendicare.com
• Phone: 905-470-4000
• Fax: N/A
• Employees: 23,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$9.17
• High Stock Price Target: C$9.50
• Low Stock Price Target: C$8.50
• Potential Upside/Downside: -1.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C$0.68
• Trailing P/E Ratio: 13.68
• Forward P/E Ratio: 15.16
• P/E Growth: N/A
• Net Income: C$59.44 million
• Net Margins: 4.28%
• Pretax Margin: N/A
• Return on Equity: 60.00%
• Return on Assets: 7.16%

Debt

• Debt-to-Equity Ratio: 305.80
• Current Ratio: 0.60
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: C$1.39 billion
• Price / Sales: 0.56
• Cash Flow: C$2.90 per share
• Price / Cash Flow: 3.20
• Book Value: C$1.28 per share
• Price / Book: 7.27

Miscellaneous

• Outstanding Shares: 83,470,000
• Free Float: N/A
• Market Cap: C$776.27 million
• Optionable: Not Optionable
• Beta: 1.26